Search results for "Nous"

showing 10 items of 2193 documents

Efficacy and side effects of intravenous remifentanil patient-controlled analgesia used in a stepwise approach for labour: an observational study

2012

Remifentanil has a suitable pharmacological profile for labour analgesia. In this prospective, observational study, intravenous patient-controlled analgesia with remifentanil, using stepwise bolus doses without background infusion, was examined during the first and second stages of labour. Outcomes were pain reduction, maternal satisfaction, maternal and neonatal side effects and remifentanil metabolism in the neonate.Parturients with normal term singleton pregnancies were recruited. The initial remifentanil bolus dose was 0.15 μg/kg, increasing in steps of 0.15 μg/kg, with a 2-min lock-out. Pain scores using a 100 mm visual analogue scale, systolic and diastolic blood pressures, respirator…

AdultRespiratory rateVisual analogue scalemedicine.medical_treatmentSedationRemifentanilBlood PressureRemifentanilYoung AdultBolus (medicine)PiperidinesHeart RatePregnancymedicineHumansPain ManagementProspective StudiesMaternal-Fetal ExchangePain MeasurementLabor PainLabor ObstetricPatient-controlled analgesiabusiness.industryInfant NewbornObstetrics and GynecologyAnalgesia Patient-ControlledAnalgesics OpioidTreatment OutcomeAnesthesiology and Pain MedicinePatient SatisfactionAnesthesiaApgar ScoreAnalgesia ObstetricalFemaleApgar scoremedicine.symptombusinessmedicine.drugIntravenous Patient-Controlled AnalgesiaInternational Journal of Obstetric Anesthesia
researchProduct

Beta-adrenergic blocking activity and haemodynamic effects in man of K� 1313, a new beta-adrenergic antagonist

1971

The beta-adrenergic blocking activity and haemodynamic effects of o-[2-hydroxy-3-(isopropylamino)-propoxy]-benzonitril (Ko 1313) have been studied in 22 patients. Antagonism of isoproterenol-induced tachycardia was used as a measure of the beta-adrenergic blocking activity. Ko 1313 1.0 mg had its maximum beta-adrenoceptor blocking effect 5–30 min after intravenous injection. Ko 1313 10.0 mg produced maximum betablockade 1–4 h after oral administration. 1.0 mg Ko 1313 injected intravenously had approximately the same beta-adrenergic blocking effect as 1.0 mg propranolol also given intravenously. After intravenous administration Ko 1313 was 3–4 times as potent as the same dose given orally. A…

AdultTachycardiamedicine.medical_specialtyCardiac outputAdolescentAdrenergic receptorCardiac VolumeAdrenergic beta-AntagonistsAdministration OralBlood Pressure1-PropanolPropranololPharmacologyElectrocardiographyHeart RateOral administrationInternal medicineNitrilesHeart ratemedicineHumansPharmacology (medical)Cardiac OutputPharmacologyBeta-adrenergic blocking agentPropylaminesbusiness.industryHemodynamicsIsoproterenolGeneral MedicineMiddle AgedAmino AlcoholsPropranololDose–response relationshipEndocrinologyInjections IntravenousSympatholyticsVascular Resistancemedicine.symptombusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

A quantitative study of the pancuronium antagonism at the motor endplate in human organophosphorus intoxication

1995

Nine patients with organophosphorus (OP) intoxication developing neuromuscular transmission defects were given pancuronium 1, 2, or 4 mg intravenously (IV). Thirteen patient controls with hypoxic encephalopathy received similar dosages. The responses were monitored electrophysiologically using single and repetitive nerve stimulation (20 and 50 Hz). In OP patients, pancuronium did not alter the amplitude of the single CMAP, whereas its repetitive discharges were reduced. Severe neuromuscular blocks were reversed only partially by pancuronium 4 mg. In less severe blocks, 1 and 2 mg resulted in marked improvement. In the patient controls, pancuronium 4 mg induced a severe neuromuscular block b…

AdultTime FactorsPhysiologymedicine.medical_treatmentNeuromuscular transmissionAction PotentialsElectromyographyMotor EndplateSynaptic TransmissionNeuromuscular junctionCellular and Molecular Neurosciencechemistry.chemical_compoundOrganophosphate PoisoningPhysiology (medical)medicineHumansPancuroniumRepetitive nerve stimulationAntidoteNeuromuscular BlockadeMovement DisordersDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryNeuromuscular DiseasesAcetylcholinesteraseElectric Stimulationmedicine.anatomical_structurechemistryAnesthesiaInjections IntravenousToxicityAcetylcholinesteraseNeurology (clinical)businessMuscle & Nerve
researchProduct

NO Reduces PMN Adhesion to Human Vascular Endothelial Cells Due to Downregulation of ICAM-1 mRNA and Surface Expression

2000

Reperfusion damage is largely due to the adherence of polymorphonuclear leukocytes to the endothelium initiated by adhesion molecule upregulation. The reduced endothelial nitric oxide release during ischemia may be involved in the upregulation of intercellular adhesion molecule 1. In this study, we tested if nitric oxide donors suppress polymorphonuclear leukocyte adherence to activated endothelial cells by inhibition of the intercellular adhesion molecule 1 surface expression. Confluent human umbilical vein endothelial cells were stimulated with tumor necrosis factor alpha (300 U/mL) after preincubation with increasing concentrations of the nitric oxide donors CAS 1609 (0.005-5 mM/L) and 3…

AdultUmbilical VeinsEndotheliumNeutrophilsIntercellular Adhesion Molecule-1Cell Culture TechniquesDown-RegulationNitric Oxide Synthase Type IINitric OxideTransfectionUmbilical veinNitric oxidechemistry.chemical_compoundmedicineCell AdhesionHumansSaphenous VeinRNA MessengerICAM-1biologyTumor Necrosis Factor-alphaMembrane ProteinsHematologyIntercellular Adhesion Molecule-1Molecular biologyEndothelial stem cellNitric oxide synthasemedicine.anatomical_structurechemistryBiochemistryGene Expression Regulationbiology.proteinTumor necrosis factor alphaEndothelium VascularNitric Oxide Synthase
researchProduct

Thromboembolic events in patients with influenza. A scoping review.

2022

Introduction: Influenza is an acute respiratory infection that usually causes a short-term and self-limiting illness. However, in high-risk populations, this can lead to several complications, with an increase in mortality. Aside from the well-known extrapulmonary complications, several studies have investigated the relationship between influenza and acute cardio and cerebrovascular events. Reviews of the thromboembolic complications associated with influenza are lacking. Objectives: the study aims to conduct a scoping review to analyze the epidemiological and clinical characteristics of patients suffering from influenza and thromboembolic complications. Materials and methods: A computerize…

AdultVenous ThrombosisInfectious DiseasesVirologyThromboembolismflu infarct influenza stroke thromboembolism thrombosisHumansThrombosisChildPulmonary EmbolismIschemic Stroke
researchProduct

Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline

2016

AdultVenous ThrombosisParenteral Nutritionmedicine.medical_specialtyNutrition and DieteticsAdult patientsbusiness.industryAnticoagulantsVenous ThromboembolismGuideline030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinemedicine.diseaseThrombosis03 medical and health sciencesVenous thrombosis0302 clinical medicineParenteral nutritionmedicineHumans030211 gastroenterology & hepatologyParenteral Nutrition HomeIntensive care medicinebusinessVenous thromboembolism
researchProduct

The Retrotransverse Foramen of the Atlas Is not a Modern Anatomic Variation

2019

Background The retrotransverse foramen (RTF) is a nonmetric variant of the atlas vertebra that consists of an abnormal accessory foramen located on the posterior root of the transverse process and it extends from the posterior root of the transverse process to the root of the posterior arch. Its presence has been related to regional variations of the venous circulation. It is currently unknown whether the RTF is a modern or an ancient anatomic variation. Case Description We analyzed the skeletal remains from the late-ancient Roman necropolis (II-VI centuries ad ) of La Boatella (Valencia, Spain) and we found a well-preserved individual skeleton that presented with a left retrotransverse for…

AdultVenous circulationRoman WorldAtlas vertebra03 medical and health sciences0302 clinical medicineAtlas (anatomy)medicineForamenHumansCervical AtlasHistory Ancientbusiness.industryAnatomic VariationAnatomyMiddle AgedCase descriptionAnatomic VariationhumanitiesPosterior archmedicine.anatomical_structure030220 oncology & carcinogenesisFemaleSurgeryNeurology (clinical)businessPosterior root030217 neurology & neurosurgeryWorld Neurosurgery
researchProduct

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris

1996

Percutaneous transluminal coronary angioplasty is often complicated by thrombotic abrupt vessel closure in patients with unstable angina pectoris. The present multicentre trial was performed to determine the feasibility of two-dose regimens of recombinant hirudin (r-hirudin) compared to standard heparin in patients undergoing coronary angioplasty for unstable angina, and to investigate the effects of the different treatment regimen on markers of coagulation activation. At five participating centres, 61 patients were randomly enrolled in one of two sequential groups of r-hirudin (group 1: 0.3 mg.kg-1 i.v. bolus, 0.12 mg.kg-1.h-1 i.v. infusion; 21 patients; group 2: 0.5 mg.kg-1 i.v. bolus, 0.…

Adultmedicine.drug_classmedicine.medical_treatmentHirudinEnzyme-Linked Immunosorbent AssayAnginaFibrinolytic AgentsmedicineHumansAngina UnstableAngioplasty Balloon CoronaryInfusions IntravenousBlood CoagulationAgedBlood coagulation testDose-Response Relationship Drugmedicine.diagnostic_testHeparinUnstable anginabusiness.industryAnticoagulantThrombinAnticoagulantsPercutaneous coronary interventionHeparinHirudinsMiddle Agedmedicine.diseaseRecombinant ProteinsAnesthesiaPartial Thromboplastin TimeDrug MonitoringCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugPartial thromboplastin timeEuropean Heart Journal
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct